PF 5230901

Drug Profile

PF 5230901

Alternative Names: PF-05230901; PF-5230901

Latest Information Update: 18 Aug 2011

Price : $50

At a glance

  • Originator Pfizer
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cachexia

Most Recent Events

  • 11 Aug 2011 Discontinued - Phase-I for Cachexia in USA (SC)
  • 05 Aug 2011 Pfizer completes enrolment in its phase I trial for Cachexia in USA (NCT01262690)
  • 30 Nov 2010 Phase-I clinical trials in Cachexia in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top